Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-08-16
2002-08-20
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S523000, C514S408000, C514S349000, C514S631000, C514S906000, C424S424000, C424S422000, C424S725000, C424S776000, C800S012000
Reexamination Certificate
active
06436937
ABSTRACT:
The invention is directed at a device and a procedure for the treatment of Alzheimer's dementia with deoxypeganine and/or a pharmaceutically acceptable acid addition salt of deoxypeganine.
Alzheimer's dementia (Alzheimer's disease, senile dementia of the Alzheimer type, SDAT, AD, presenile dementia, senile dementia, primary degenerative dementia, PDD) is understood as meaning the clinical manifestation of a disturbance of the most highly developed areas of the brain. More precise descriptions can be gleaned, for example, in L. L. Heston et al., Arch. Gen. Psychiatry, (1981) 1085 or in R. Terry, R. Katzman: “Senile Dementia of the Alzheimer Type: Defining a Disease” in The Neurology of Aging, ed.: R. Katzman, Chapter 3, p. 51.
An exact diagnosis of Alzheimer's dementia is only possible post mortem by autopsy. For the person skilled in the art, however, it is possible on the basis of typical symptoms (increasing loss of intellectual capabilities and memory loss in the early stage; confusion, loss of the sense of orientation, abnormal sensory liability, depression, anxiety states, lack of motivation, disturbed social behavior, tiredness, weakened driving force, loss of weight etc. in the advanced stage) and in the absence of references to other causes to diagnose Alzheimer's dementia with high probability.
The cause of Alzheimer's dementia is still not known even today. Consequently no medicinal or other therapy form exists for the causal treatment of Alzheimer's dementia.
The patient affected by Alzheimer's dementia, but particularly also the relatives directly living together with this patient, see this illness as a severe burden because of its inexorably progressive character and because death is undeniably at its end.
Many strategies have therefore been proposed to slow the progression of Alzheimer's dementia, i.e. to improve the mental (cognitive) capabilities.
The medicinal strategies include the administration of:
psychostimulants such as dihydroergotoxin,
vasodilators such as papaverine, isoxuprine, cyclandelate,
stimulants such as methylphenidate, pentylenetetrazole,
substances for improving the cerebral blood circulation such as naftidofuryl, pentoxifylline, suloctidil, vincamine,
calcium channel blockers such as nimodipine,
nootropic substances such as piracetam, oxiracetam, rolziracetam, pramiracetam, aniracetam, Cl-844, Cl-933,
cholinergic active compounds such as arecoline, physostigmine, RS-86, bethanecol, BM-5,
analogs of ACTH such as ORG 2766,
vasopressins, such as DDAVP, DGAVP
somatostatin, such as L-363,586
serotonin active compounds such as alaproclate, zimelidine,
adrenergic substances such as clonidine,
hormones such as estradiol
but also of vitamins, lecithin, nicotine, tacrine and others.
It is the object of the present invention to make available a device and a procedure by means of which the symptoms of patients having Alzheimer's dementia are reduced. In particular the cognitive capabilities of these patients should be improved or the progressive character of the decrease in the mental faculties should be slowed. The object of the invention thus consists not in treatment in the classical sense with the objective of cure, but a palliative treatment of the symptoms in order to make possible to the patient a largely independent conduct of life and thus to make the care of the patient easier for the relatives and the nursing staff.
The object is achieved by a device which is capable of delivering the active compound deoxypeganine and/or a pharmaceutically acceptable acid addition salt of deoxypeganine to the patient.
Deoxypeganine is an alkaloid of the empirical formula C
11
H
12
N
2
having the above structure, which is contained in plants of the Zygophyllaceae family. It is commercially obtainable as an acid addition salt (hydrochloride C
11
H
12
N
2
.HCI.H
2
O).
REFERENCES:
patent: 5750542 (1998-05-01), Villalobos et al.
patent: WO 97/23484 (1997-07-01), None
Database WPI Section Ch, Week 197913 Derwent Publications Ltd., London, GB; Class B02, AN 1979-25213B (XP002139611).
Database WPI Section Ch, Week 198235 Derwent Publications Ltd., London, GB; Class B04, AN 1982-74317E (XP002139612).
Muratova, et al, “Toxicology of the new pharmaceutical preparation of dehydroxypeganine hydrochloride” Med. Zh. Uzb. 1984, (1), 53-5 (XP000957819) (abstract).
Heston et al, “Dementia of the Alzheimer Type” Arch. Gen. Psychiatry 1981, vol. 38 pp. 1085-1090.
Terry et al., “Senile Dementia of the Alzeimer Type: Defining A Disease” The Neurology of Aging, by Robert Katzman 1983, Ch.3, pp. 51-84.
Asmussen Bodo
Hille Thomas
Hoffmann Hans-Rainer
Opitz Klaus
Frommer & Lawrence & Haug LLP
LTS Lohman-Therapie Systeme AG
LandOfFree
Use of desoxypeganine in the treatment of Alzheimer's... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of desoxypeganine in the treatment of Alzheimer's..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of desoxypeganine in the treatment of Alzheimer's... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2924366